Savara

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. 

CEO
Matthew Pauls
CEOMatthew Pauls
Employees
59
Employees59
Headquarters
Langhorne, Pennsylvania
HeadquartersLanghorne, Pennsylvania
Founded
1995
Founded1995
Employees
59
Employees59

SVRA Key Statistics

Market cap
1.32B
Market cap1.32B
Price-Earnings ratio
-12.15
Price-Earnings ratio-12.15
Dividend yield
Dividend yield
Average volume
3.84M
Average volume3.84M
High today
$6.58
High today$6.58
Low today
$6.31
Low today$6.31
Open price
$6.40
Open price$6.40
Volume
4.02M
Volume4.02M
52 Week high
$6.61
52 Week high$6.61
52 Week low
$1.89
52 Week low$1.89

Stock Snapshot

Savara(SVRA) stock is priced at $6.50, giving the company a market capitalization of 1.32B. It carries a P/E multiple of -12.15.

During the trading session on 2025-12-08, Savara(SVRA) shares reached a daily high of $6.58 and a low of $6.31. At a current price of $6.50, the stock is +3.0% higher than the low and still -1.1% under the high.

Trading volume for Savara(SVRA) stock has reached 4.02M, versus its average volume of 3.84M.

The stock's 52-week range extends from a low of $1.89 to a high of $6.61.

The stock's 52-week range extends from a low of $1.89 to a high of $6.61.

SVRA News

Simply Wall St 5d
Savara: Valuation Check After New European Patent Win and Rising Conference-Driven Investor Interest

Savara (SVRA) has been back on traders radar after securing a European patent for its Molbreevi drug device combo, just as management heads into high profile he...

Savara: Valuation Check After New European Patent Win and Rising Conference-Driven Investor Interest

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own SVRA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.